---
layout: default
title: Nadolol
parent: 僅模型預測 (L5)
nav_order: 538
evidence_level: L5
indication_count: 5
---

# Nadolol
{: .fs-9 }

證據等級: **L5** | 預測適應症: **5** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Nadolol: From Hypertension to Malignant Renovascular Hypertension

## One-Sentence Summary

Nadolol is a non-selective beta-adrenergic blocker traditionally used for systemic blood pressure and cardiac rate control. The TxGNN model predicts it may be effective for **Malignant Renovascular Hypertension**, but this prediction currently has **no supporting clinical trials or literature** — it rests entirely on the model's score.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Hypertension (general beta-blocker indication; drug is not marketed in Canada, so no local approved-label text is available) |
| Predicted New Indication | Malignant Renovascular Hypertension |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 |
| Canada Market Status | ✗ Not marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, Nadolol is a non-selective beta-adrenergic blocker; its efficacy in general hypertension control has been established, and mechanistically it may be applicable to malignant renovascular hypertension through systemic blood pressure reduction and reduced sympathetic/renin-driven cardiac output.

However, the connection is theoretical only. Malignant renovascular hypertension is typically driven by renal artery stenosis and activation of the renin-angiotensin system; definitive management usually requires addressing the renal artery lesion itself (e.g., revascularization), not blood pressure control alone. There is no drug-specific evidence — clinical, trial, or literature — for nadolol in this particular hypertensive subtype. The prediction reflects a knowledge-graph score-based inference (rank ~8,127 out of the model's output) rather than an established or even preliminarily tested therapeutic rationale.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Canada Market Information

Nadolol is not currently marketed in Canada (0 DINs / licenses on record); no product or approved-indication data is available for this jurisdiction.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This prediction is supported only by a TxGNN model score (L5, decision stage S0) — there are zero clinical trials, zero literature citations, and no drug-specific evidence for nadolol in malignant renovascular hypertension. The proposed mechanism also conflicts with standard clinical management of this condition, which typically requires renal artery intervention rather than beta-blockade alone.

**To proceed, the following is needed:**
- TFDA/regulatory label warnings and contraindications (currently a blocking data gap — required before any safety pre-assessment)
- Confirmed mechanism of action (MOA) data from DrugBank or equivalent source
- Disease-specific preclinical or case-level evidence linking nadolol to renovascular/malignant hypertension subtypes
- Clarification of whether this indication is already implicitly covered under nadolol's existing general antihypertensive use, which would reduce novelty
- Basic DDI and contraindication profile, since all current safety fields are unpopulated
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

